Group 1 - The new hypertension treatment drug, Xinchaotuo® (Sacubitril/Alesartan Calcium Tablets), has been launched online by JD Health and is the first original ARNI (Angiotensin Receptor Neprilysin Inhibitor) antihypertensive drug developed in China, offering superior and safer blood pressure control [2] - Xinchaotuo® is the first ARNI drug developed in China and the second ARNI co-crystal drug globally, featuring a design that synchronizes the peak effects of its active metabolite, Sacubitril, and Alesartan, thereby extending the half-life of Alesartan and improving blood pressure control [2] - ARNI drugs not only provide effective blood pressure reduction but also offer heart and kidney protection, making them particularly suitable for patients with hypertension combined with heart failure or chronic kidney disease [2] Group 2 - Xinli Tai Pharmaceutical has strategically focused on the hypertension treatment area, developing a complete family of original Alesartan antihypertensive drugs, including single-agent and combination formulations [3] - JD Health aims to leverage its capabilities to help Xinchaotuo® reach a broader patient base, enhancing the treatment level for hypertension in China through this collaboration [3] - JD Health has been recognized as the "first station for the online launch of new specialty drugs," continuously expanding its value effect and providing innovative drug access to a wide range of patients [3]

Core Viewpoint - The company has received approval from the National Medical Products Administration for its newly developed drug, Sacubitril/Valsartan Calcium Tablets (Xinchao Tuo), which is indicated for primary hypertension and represents a significant advancement in the ARNI class of medications [1] Group 1: Drug Approval and Characteristics - The drug is the first original research product in China and the second globally approved ARNI medication, with a compound patent protection period extending until 2037 [1] - Phase III clinical trial results indicate significant antihypertensive efficacy with a clear dose-dependent response [1] Group 2: Strategic Positioning - Following the launch of Xinchao Tuo, the company will enhance its competitive position in the cardiovascular chronic disease treatment sector by complementing its existing products, Xintan and Fulitan, to meet a broader range of clinical needs [1]